Search for content, post, videos

Salipro Biotech obtains grant for key patent

Jens Frauenfeld Salipro Biotech

The European Patent Office (EPO) has granted a further patent in Salipro Biotech’s patent portfolio: European Patent entitled “Production of Salipro particles”.

This patent covers processes related to the Salipro platform and represents a pivotal milestone that strengthens Salipro Biotech’s position as a key drug discovery platform holder for difficult drug targets such as GPCRs, ion channels and transporters, states the company.

“We are excited about this advancement on our intellectual property portfolio and the Salipro platform technology. This patent further solidifies our position by complementing our foundational and subsequent patents that have already been granted in many countries, including US, EU, China and Japan,” says Jens Frauenfeld, CEO of Salipro Biotech. “This is another significant milestone for Salipro Biotech in building a robust patent portfolio that protects our unique platform technology and supports our commitment to make the undruggable druggable.”

This patent is based on one of multiple patent filings of Salipro Biotech since 2016.

Photo of Jens Frauenfeld: Salipro